weight-lossclinical-trials
Retatrutide
Retatrutide (LY3437943)
Overview
A triple hormone receptor agonist (GLP-1/GIP/Glucagon) in clinical trials by Eli Lilly. Shows remarkable weight loss results up to 29% body weight. Often misleadingly called "GLP-3" on gray market.
Mechanism of Action
Activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon component may provide additional metabolic benefits and fat burning.
Popular Research Uses
- Weight loss (investigational)
- Metabolic health (investigational)
Potential Side Effects
- Nausea (reported in trials)
- Diarrhea
- Vomiting
- Constipation
- Unknown - trials ongoing
Warnings
- NOT FDA approved - still in clinical trials
- Gray market versions are untested and potentially dangerous
- "GLP-3" is a marketing term, not accurate
- No established safety profile
- Unknown long-term effects
Dosage Information
DO NOT use gray market versions. Wait for FDA approval and proper medical guidance.